ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today submitted a New Drug Application…

View More ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV

REGENERON AND ALNYLAM ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range…

View More REGENERON AND ALNYLAM ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES